Oct 17, 2018
Eisai and Purdue Pharma Announce Positive Topline Results of SUNRISE 2, the Second Phase 3 Pivotal Study of Lemborexant
Oct 09, 2018
Bayer to Showcase Latest Oncology Research at ESMO 2018 Congress
Sep 28, 2018
Eisai Announces FDA Approval Of FYCOMPA® in Pediatric Patients As Young As 4 Years Old For The Treatment Of Partial-Onset Seizures
Sep 11, 2018
BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study
Sep 11, 2018
Health-Related Quality of Life Maintained with Addition of ERLEADA® to Androgen Deprivation Therapy for Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Aug 07, 2018
Syndax Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Clinical and Business Update
Jul 24, 2018
China Imatinib Market Report 2018-2022: Basic Concepts, Sales, Major Manufacturers, Prices & Market Prospects
Jul 18, 2018
Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
Jul 18, 2018
FDA approves first cancer drug through new oncology review pilot that enables greater development efficiency
Jul 04, 2018
Health Canada Approves ERLEADA(TM)* (apalutamide tablets), the First Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer
Jun 21, 2018
Blueprint Medicines Initiates VOYAGER Phase 3 Clinical Trial of Avapritinib in Patients with Advanced Gastrointestinal Stromal Tumors
Jun 19, 2018
Medisafe Announces Partnership with Boehringer Ingelheim to Support U.S. Pradaxa Patients
Jun 18, 2018
Champions Oncology Partners with Puma Biotechnology and NSABP Foundation on Metastatic Breast and Colon Cancer Co-clinical PDX Studies
Jun 03, 2018
Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer
Jun 02, 2018
New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy
May 17, 2018
Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
May 16, 2018
Lilly Data at ASCO Illustrate Patient-Driven Advances in Cancer Care
May 01, 2018
Case Report in Journal of Thoracic Oncology Demonstrates the Clinical Utility of Biocept's Liquid Biopsy Test for Patient Diagnosed with Non-Small Cell Lung Cancer
Apr 25, 2018
Syndax Pharmaceuticals Announces Presentations at the 2018 American Society of Clinical Oncology Annual Meeting
Apr 11, 2018
Perrigo Launches Novel Omeprazole Orally Disintegrating Tablet to Treat Frequent Heartburn